Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research CongressPresentations will highlight Phase 2b OPTI-2 findings demonstrating the potential of HDV-insulin lispro to maintain glycemic control while reducing hypoglycemia in adults with type 1 diabetes
Diasome Pharmaceuticals Strengthens Leadership Team as Company Prepares for Phase 3 DevelopmentExperienced pharmaceutical R&D leader Sangeeta Sawhney, M.D., appointed Chief Medical Officer to lead clinical development as Diasome advances HDV-Insulin toward Phase 3
